David Morris, MD, FACS

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

Mechanisms of Action and Differentiation Among ARPI Therapies in mCSPC

Current Treatment Landscape and Guideline Recommendations in mCSPC

Explore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.

Explore the coordinated approach between urologists and medical oncologists to ensure smooth transitions and ongoing care for patients receiving combination therapies in prostate cancer treatment.

Join experts David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss the barriers and considerations in prescribing triplet therapy, offering insight into its benefits and how collaborative care between urologists and medical oncologists ensures a seamless patient journey.

Discover considerations for doublet or triplet therapy in advanced prostate cancer, analyzing the benefits and manageable added toxicity, as discussed by renowned experts in the field.

Join key opinion leaders as they analyze the evolving landscape of metastatic HSPC, delving into the advantages and key factors to consider with triplet combination therapies, encompassing chemotherapy and ARPI agents.

Explore the evolving landscape of hormone therapies in prostate cancer treatment with insights from expert physicians as they delve into the latest options, indications, and their impact on patient care.

A brief review of the evolving realm of prostate cancer care centered on the significance of identifying high-risk cases and addressing the complexities of risk stratification and prognosis.

A discussion surrounding the changing landscape of early-stage prostate cancer screening and rise in metastatic disease cases, focusing on the importance of timely intervention and patient-focused care.

Delve into the strategic process of selecting ideal partners in cancer care as key opinion leaders share insights on building trust, effective communication, and optimizing patient outcomes through collaborative decision making.

Explore how David Morris, MD, FACS, and Benjamin Garmezy, MD, join forces to enhance patient outcomes in advanced prostate cancer through their innovative and collaborative precision medicine strategies.

Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.

The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.

Drs Cookson and Sellinger discuss the remaining unmet needs in imaging for patients with prostate cancer.

The panel shares their perspectives on the transition to virtual multidisciplinary tumor boards for patients with prostate cancer after the COVID-19 pandemic.

Delving deeper into PSMA-PET results interpretation and information sharing, panelists outline the most critical information needed from radiologists and urologists on a patient’s multidisciplinary care team.

Experts share potential solutions to overcome the clinical challenges of using PSMA-PET in practice, including use of reader training programs.

Dr Cookson discusses the challenges of using PSMA-PET imaging in prostate cancer, including reimbursement and patient access.

Dr Sellinger details the range of clinical guidelines on the use of PSMA-PET imaging in prostate cancer and which he is most likely to follow.

The panel reviews clinical data and provides real-world insight on how use of PSMA-PET imaging has impacted the management of patients with prostate cancer.

Experts discuss practical considerations on selection among available PSMA-PET tracer options for prostate cancer imaging, including regional availability, scheduling, and preparation requirements.

The panel reviews the similarities and differences between the FDA-approved PSMA-PET tracer options for prostate cancer imaging.

Phillip Koo, MD, defines prostate-specific membrane antigen (PSMA) and explains the rationale for use as a target in PET-based prostate cancer imaging.

Scott Sellinger, MD, FACS, shares a historical perspective on use of conventional imaging modalities in prostate cancer.

Michael Cookson, MD, MMHC, explains the NCCN criteria used to stratify patients with clinically localized prostate cancer into risk groups.